Investor Stock List
Ranked #5,404 of 8,699 institutional investors

Krensavage Asset Management, LLC

New York, NY

$256M
US stock portfolio at live prices · today −$1.7M (−0.67%)
Live prices, last trade 11:34 AM ET
Value at quarter end (Q3 2026)
$265M
Change from Q2 2026
+$2.2M (+0.82%)
Positions
17 · 3 new, 1 sold out
Filed
Nov 17, 2026

Not counted in the ranking: none$55.7M of holdings we could not match to a US listing are included at their reported quarter-end value.

Holdings

Q3 2026 13F, live prices
UTHR 14.4%BMRN 12.5%ENTA 8.60%ABT 8.14%EXEL 7.73%
StockSharesValue, live% of portfoliovs Q2 2026
UTHR United Therapeutics Corporation66,282$36.8M14.4%Reduced −4%
BMRN BioMarin Pharmaceutical Inc.524,786$32.0M12.5%Unchanged
ENTA Enanta Pharmaceuticals, Inc.2,866,138$22.0M8.60%Unchanged
ABT Abbott Laboratories200,000$20.8M8.14%Unchanged
EXEL Exelixis, Inc.299,393$19.8M7.73%Reduced −19%
RARE Ultragenyx Pharmaceutical Inc.1,140,867$19.0M7.44%Added +192%
SNY Sanofi333,946$15.6M6.08%Added +3%
EMBC Embecta Corp.1,135,340$7.1M2.78%Unchanged
ARDX Ardelyx, Inc.1,815,492$5.4M2.13%Added +240%
BIIB Biogen Inc.20,000$5.0M1.95%Unchanged
BNTX BioNTech SE59,523$4.8M1.89%Unchanged
GSK GSK plc96,729$4.7M1.83%Unchanged
VNDA Vanda Pharmaceuticals Inc.1,180,388$4.2M1.65%Unchanged
ANIP ANI Pharmaceuticals, Inc.13,000$892K0.35%New
ZTS Zoetis Inc.10,000$812K0.32%New
ACAD Acadia Pharmaceuticals Inc.40,000$702K0.27%New
EOLS Evolus, Inc.57,985$403K0.16%Reduced −63%

Sold out in Q3 2026

StockShares held at Q2 2026Worth today
REGN Regeneron Pharmaceuticals, Inc.6,000$5.6M